Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

Open access
Barthélemy, Nicolas R., Horie, Kanta, Sato, Chihiro, Bateman, Randall J. · 2020 · Journal of Experimental Medicine

Abstract

Highly sensitive and specific plasma biomarkers for Alzheimer’s disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of β-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms’ profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20200861

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC-SA · PubMed Central
Figure 1. Plasma tau truncation profile after chemical extraction and IP in the discovery cohort. Left: Plasma tau peptides concentration profiles obtained from the 36 individuals. Each line corresponds to the peptide profile from one participant. Right: Dots represents averaged tau peptides normalized concentration obtained from the overall cohort. Normalized concentration for each peptide is relative to the sum of the peptides concentrations measured in each participant. Bars represent SD. Label a indicates a decrease of 2N and 1N+2N peptide abundance consistent with 5/5/1 0N/1N/2N contribution in plasma tau. Label b indicates a decrease consistent with the presence of around 10% of phosphorylation on position 181. Phosphorylation on T181 induces a trypsin missed cleavage between residues 180 and –181. This contributes to a decrease of 175–180 and 181–190 peptides abundance proportional to the extent of phosphorylation on T181. Label c indicates a decrease consistent with tau truncation between residues 221 and 226. Cicognola et al. (2019) have reported CSF tau main cleavage occurring at residue 224. Label d indicates a decrease consistent with progressive C terminus degradation of plasma tau from residue 224 to microtubule binding region upstream region.
Figure 1. Plasma tau truncation profile after chemical extraction and IP in the discovery cohort. Left: Plasma tau peptides concentration profiles obtained from the 36 individuals. Each line corresponds to the peptide profile from one participant. Right: Dots represents averaged tau peptides normalized concentration obtained from the overall cohort. Normalized concentration for each peptide is relative to the sum of the peptides concentrations measured in each participant. Bars represent SD. Label a indicates a decrease of 2N and 1N+2N peptide abundance consistent with 5/5/1 0N/1N/2N contribution in plasma tau. Label b indicates a decrease consistent with the presence of around 10% of phosphorylation on position 181. Phosphorylation on T181 induces a trypsin missed cleavage between residues 180 and –181. This contributes to a decrease of 175–180 and 181–190 peptides abundance proportional to the extent of phosphorylation on T181. Label c indicates a decrease consistent with tau truncation between residues 221 and 226. Cicognola et al. (2019) have reported CSF tau main cleavage occurring at residue 224. Label d indicates a decrease consistent with progressive C terminus degradation of plasma tau from residue 224 to microtubule binding region upstream region.CC BY-NC-SA · PubMed Central
Figure 2. Plasma tau and p-tau changes across groups in Tau SILK discovery cohort. (A) Measures of p-tau-217/T217 ratios in plasma and CSF are highly correlated in both entire cohort and CSF p-tau-217 positive subgroup. Spearman correlations and associated P value are shown. (B–E) Separation between amyloid-negative and -positive groups are calculated using AUROC. (B and C) Consistent with CSF measurement, plasma p-tau-217/T217 ratio and p-tau-217 level distinguish amyloid-negative from amyloid-positive groups regardless of the cognitive status. Amyloid-negative groups with high CSF p-tau-217 were also separated from other amyloid-negative groups. (D) Plasma tau level is not a biomarker for amyloid status and AD dementia. (E and F) Plasma p-tau-181/T181 ratio and p-tau-181 level increase in amyloid-positive groups. YNC, young normal controls; AMC, aged-matched controls.
Figure 2. Plasma tau and p-tau changes across groups in Tau SILK discovery cohort. (A) Measures of p-tau-217/T217 ratios in plasma and CSF are highly correlated in both entire cohort and CSF p-tau-217 positive subgroup. Spearman correlations and associated P value are shown. (B–E) Separation between amyloid-negative and -positive groups are calculated using AUROC. (B and C) Consistent with CSF measurement, plasma p-tau-217/T217 ratio and p-tau-217 level distinguish amyloid-negative from amyloid-positive groups regardless of the cognitive status. Amyloid-negative groups with high CSF p-tau-217 were also separated from other amyloid-negative groups. (D) Plasma tau level is not a biomarker for amyloid status and AD dementia. (E and F) Plasma p-tau-181/T181 ratio and p-tau-181 level increase in amyloid-positive groups. YNC, young normal controls; AMC, aged-matched controls.CC BY-NC-SA · PubMed Central
Figure S1. Spike and recovery experiment assessing assay performance using 4 ml of plasma volume. Plasma pool or 5% solution of recombinant HSA were spiked with increased volumes of AD or non-AD CSF pools. Plasma was extracted using the 4-ml protocol described in the Materials and methods. HSA samples were only immuno-purified (IP) before digestion and analysis.
Figure S1. Spike and recovery experiment assessing assay performance using 4 ml of plasma volume. Plasma pool or 5% solution of recombinant HSA were spiked with increased volumes of AD or non-AD CSF pools. Plasma was extracted using the 4-ml protocol described in the Materials and methods. HSA samples were only immuno-purified (IP) before digestion and analysis.CC BY-NC-SA · PubMed Central
Figure 3. Plasma tau and p-tau changes across groups in Aβ SILK validation cohort. (A) Phosphorylation occupancies on T217 in plasma and CSF correlate. Spearman correlations and associated P value are shown. (B and C) As found in the discovery cohort, plasma p-tau-217/T217 ratio and p-tau-217 level distinguish amyloid-negative from amyloid-positive groups regardless of the cognitive status. Amyloid-negative with high CSF p-tau-217 were also separated from other amyloid-negative groups. Separations between groups are calculated using AUROC. (D) Plasma tau level is not a biomarker for amyloid status and AD dementia. (E and F) Plasma p-tau-181/T181 ratio and p-tau-181 level increase in amyloid-positive groups but are less accurate than p-tau-217 measures to detect abnormal tau phosphorylation. (G and H) Receiver operating characteristic curves discriminating amyloid-positive from amyloid participants using CSF and plasma tau measures. Corresponding AUCs are summarized in Table 2. AUC comparison between p-tau-217 and p-tau-181 measures is described in Table S3. (I) Plasma p-tau-217/T217 ratio associates with Aβ42/40 ratio measured in CSF.
Figure 3. Plasma tau and p-tau changes across groups in Aβ SILK validation cohort. (A) Phosphorylation occupancies on T217 in plasma and CSF correlate. Spearman correlations and associated P value are shown. (B and C) As found in the discovery cohort, plasma p-tau-217/T217 ratio and p-tau-217 level distinguish amyloid-negative from amyloid-positive groups regardless of the cognitive status. Amyloid-negative with high CSF p-tau-217 were also separated from other amyloid-negative groups. Separations between groups are calculated using AUROC. (D) Plasma tau level is not a biomarker for amyloid status and AD dementia. (E and F) Plasma p-tau-181/T181 ratio and p-tau-181 level increase in amyloid-positive groups but are less accurate than p-tau-217 measures to detect abnormal tau phosphorylation. (G and H) Receiver operating characteristic curves discriminating amyloid-positive from amyloid participants using CSF and plasma tau measures. Corresponding AUCs are summarized in Table 2. AUC comparison between p-tau-217 and p-tau-181 measures is described in Table S3. (I) Plasma p-tau-217/T217 ratio associates with Aβ42/40 ratio measured in CSF.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 476

Metadata

Authors
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J.
Affiliations
Washington University in St. Louis (US)
Corresponding author
  • Barthélemy, Nicolas R.
  • Bateman, Randall J.
Venue
Journal of Experimental Medicine
Published
2020-07-28
Volume
217
Issue
11
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W3045987239
Cited by
437
References
36
Citations by year
2026: 57 · 2025: 72 · 2024: 72 · 2023: 64 · 2022: 82 · 2021: 71 · 2020: 19
FWCI
35.50
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
Funders
  • Alzheimer’s Association (AARF-16-443265)
  • Rainwater Charitable Foundation
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke (R01NS095773)
  • Tau SILK Consortium
  • AbbVie
  • Biogen
  • Eli Lilly and Company
  • Coins for Alzheimer’s Research Trust
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
Alzheimer's disease, tau isoforms, CSF tau, plasma biomarkers, amyloid plaques, beta-amyloidosis, diagnostic accuracy, tau truncation
MeSH terms
Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Middle Aged, Phosphorylation, Mass Spectrometry, Cohort Studies, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Protein Isoforms, Positron-Emission Tomography, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. https://app.cochat.ai/papers/10.1084/jem.20200861
The paper
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020). Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20200861

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.